rs6656401 — CR1 CR1 complement receptor Alzheimer's variant

CR1 — When the Brain's Waste-Clearance Crew Falls Short

Complement receptor 1 (CR1, also known as CD35) is a molecular garbage collector. It sits on the surface of red blood cells, monocytes, and dendritic cells, binding to complement-tagged debris — including amyloid-beta oligomers¹¹ amyloid-beta oligomers
the toxic protein fragments that accumulate in Alzheimer's disease — and shuttling them to the liver and spleen for destruction. The rs6656401 variant in the CR1 gene was identified in 2009 as one of the first genome-wide significant Alzheimer's risk loci beyond APOE, and it remains among the most robustly replicated genetic risk factors for late-onset disease.

The Mechanism

CR1 mediates immune adherence²² immune adherence
the process by which complement-opsonized particles are bound to erythrocytes and carried out of circulation. When complement proteins C3b or C4b coat amyloid-beta aggregates in the bloodstream or cerebrospinal fluid, CR1 on circulating red blood cells acts as a capture receptor, escorting the tagged debris to the reticuloendothelial system. The CLU gene (clusterin), identified in the same 2009 paper, performs a complementary amyloid-chaperoning role — lending biological plausibility to both genes as amyloid-clearance machinery.

The rs6656401 A risk allele sits within an intron of CR1 and functions as a regulatory variant³³ regulatory variant
it alters CR1 expression or splicing rather than changing the amino acid sequence. A 2023 study measuring plasma protein levels showed that the A allele is significantly associated with increased soluble CR1 (sCR1) concentrations — suggesting the risk mechanism may involve a shift from membrane-bound CR1 (the functional form on erythrocytes) to its soluble, shed isoform. Elevated sCR1 in plasma is believed to act as a decoy receptor, competing with and potentially inhibiting the erythrocyte-bound CR1 that performs physiological clearance.

The Evidence

Lambert et al. (2009) in Nature Genetics⁴⁴ Lambert et al. (2009) in Nature Genetics
first GWAS to identify CR1 as an AD risk locus beyond APOE reported an odds ratio of 1.21 (95% CI 1.14–1.29, P=3.7×10⁻⁹) for the rs6656401 A allele in a combined European dataset of over 9,000 individuals. The association was validated across five independent European cohorts, establishing CR1 as a genuine LOAD susceptibility locus.

A 2015 meta-analysis of 85,939 samples (30,100 cases; 55,839 controls) across 24 studies⁵⁵ A 2015 meta-analysis of 85,939 samples (30,100 cases; 55,839 controls) across 24 studies
the largest pooled analysis specifically of rs6656401 confirmed the association with OR=1.18 (95% CI 1.15–1.22, P=1.82×10⁻²⁶) in combined populations, and OR=1.31 in East Asian samples — a finding that highlights population-specific effect sizes likely driven by differences in genetic background and LD patterns.

Liu et al. (2021), synthesizing 30 studies with over 68,000 participants⁶⁶ Liu et al. (2021), synthesizing 30 studies with over 68,000 participants
the most comprehensive systematic review of CR1 variants in LOAD, confirmed OR=1.23 (95% CI 1.10–1.36) overall and OR=1.26 in European populations specifically, with the A allele as the risk allele in all models tested. The evidence level is strong: the association has been independently replicated across populations and study designs, and a plausible biological mechanism has been characterised. Clinical-guideline-level evidence (CPIC/DPWG) does not yet exist for CR1 because there are no genotype-specific approved interventions.

Practical Implications

Unlike pharmacogenomic variants with direct drug-dose consequences, the CR1 rs6656401 variant informs risk stratification and motivates a specific biological target: complement-mediated amyloid clearance. For A-allele carriers, the actionable focus is on supporting the complement and immune pathways that handle amyloid burden, and on early monitoring.

Erythrocyte CR1 density varies by a HindIII RFLP polymorphism⁷⁷ HindIII RFLP polymorphism
the CR1 high-density (H) and low-density (L) allele determining copy number on red cells independently of rs6656401, and the relationship between rs6656401, sCR1 levels, and erythrocyte CR1 density is an active area of research. What is clear is that the A allele shifts complement biology in a direction associated with impaired amyloid clearance and increased disease risk.

The most actionable steps for A-allele carriers center on: (1) monitoring cognitive function early to catch any changes before they become irreversible, (2) managing the modifiable complement- and inflammation-activating factors (metabolic health, sleep quality, cardiovascular fitness) that amplify amyloid accumulation, and (3) awareness that participation in prevention trials is particularly valuable given the established, replicated risk.

Interactions

The most important interaction is with APOE genotype (rs429358 + rs7412). APOE ε4 affects amyloid-beta production and aggregation via lipoprotein pathways, while CR1 affects its clearance via complement. Carrying both CR1 risk alleles and APOE ε4 may represent compounding impairment of two independent amyloid-handling systems — accumulation plus impaired removal.

BIN1 rs744373 and CLU rs11136000 also influence amyloid and tau biology through different mechanisms. While no single study has formally quantified the combined effect of all four loci, polygenic risk scores incorporating CR1, BIN1, CLU, and APOE together predict Alzheimer's risk substantially better than any single variant alone, supporting the additive model that guides action in high-risk carriers.